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from medical care interventions than from primary pre-
ventive policy measures. Gender and ethnic differences in
amenable mortality were also observed, calling attention
to issues of socioeconomic equities to be addressed in the
financing and delivery of health care.
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OBJECTIVE: To perform a policy impact analysis of
pharmaceutical cost containment strategies implemented
by a third party payer (ministry of health (MOH)), in the
province of Alberta, Canada, during the 1990s. METH-
ODS: A retrospective, pre-post policy intervention regres-
sion-based time trend analysis of seniors’ prescription
drug expenditures between July 1992 and September
1999 was used for the evaluation. All seniors (aged 65
and older) in Alberta are eligible for publically subsidized
prescription drug coverage. The policies included the in-
troduction of least cost alternative (LCA) pricing for in-
terchangeable drug products, pharmacy reimbursement
changes, an increase in the co-payment rate by seniors
from 20% to 30%, and the introduction of a maximum
co-payment cap of $25 per prescription. Policies were
primarily evaluated from the societal perspective, and
economic re-distributional consequences were also exam-
ined. RESULTS: Total drug expenditures for 1999 were
approximately Can$230 million (M) for the 300,000 eli-
gible beneficiaries (seniors) in Alberta. The LCA and
pharmacy reimbursement policies reduced overall soci-
etal costs by approximately 10%, or Can$21.3M in 1999
(95% CI 7.4M–34.5M); the ministry saved Can$18.1M
(95% CI 7.0M–29.2M) and out-of-pocket costs to se-
niors were reduced Can$3.6M (95% CI 0.2M–7.0M). An
increase in the coinsurance rate and introduction of a
maximum cap did not significantly decrease total drug
expenditures, but the MOH realized significant savings
of Can$18.0M (95% CI 4.6M–31.3M) while drug costs
to seniors increased by Can$10.2M (95% CI 6.0M–14.3M)
in 1999. CONCLUSION: The LCA and pharmacy reim-
bursement restructuring policies were effective in signifi-
cantly decreasing overall drug costs to society. The in-
crease in the co-insurance rate and introduction of a cap
resulted in significant savings for the ministry but was
achieved by shifting costs to seniors, raising issues of ac-
cess and equity.
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A number of countries have developed pharmacoeco-
nomic (PE) guidelines for three objectives: regulatory re-
quirements, standardization of methods, implementation
of Good PE Practice. At least 18 countries have issued
such guidelines. OBJECTIVES: To compare and contrast
existing guidelines for their usefulness and relevance for
the practising health economist. Specifically, we aimed to
highlight areas of agreement and dissent, and identify is-
sues with practical implications in the different countries.
METHODS: Existing documents were reviewed, ana-
lyzed, and a comparison undertaken. The following top-
ics were considered when reviewing the documents: (1)
objective (pricing and reimbursement, formulary inscrip-
tion, state of the art), (2) degree of precision and pre-
scription, (3) international consensus and (4) divergence
(type of analyses, comparator, perspective, costing and
implementation). Within each topic, issues addressed by
the countries have been identified, and any recommenda-
tions promulgated have been compared. RESULTS: Ac-
cording to the degree of guideline prescription, three
groups of countries can be identified: “soft” guidelines
including countries such as Finland and Belgium; “mod-
erate” guidelines such as Canada and Denmark and
“strict” guidelines such as Australia and the Netherlands.
For a number of issues, recommendations are consistent
between the countries. For example, all national docu-
ments recommend that a societal perspective should be
adopted and economic data should be described in both
natural and monetary units. By contrast, there is a lack of
consensus concerning costing. CONCLUSIONS: This work
indicates that collaboration across countries and between
sponsors, researchers and decision-makers is essential to
reach an optimal degree of agreement and to perform
convincing and useful studies. When designing an inter-
national PE study, it is essential to take into account local
guideline requirements as they may lead to practical im-
plications.
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OBJECTIVE: To investigate the usefulness of published
economic evaluations to health authority decision-mak-
ers in the UK National Health Service. METHODS: Fo-
cus group discussions were conducted in two health au-
thorities. In a preliminary meeting in both authorities,
groups of decision-makers were (i) asked general ques-
tions about their needs for economic evidence in the pro-
cess of resource allocation and (ii) invited to specify top-
ics for which they would find economic evidence useful.
Prior to a second meeting the NHS Economic Evaluation
Database (NHS EED) was searched to identify critical re-
views (structured abstracts) of studies pertaining to the
topics. At the second meeting the specific and general
usefulness of the abstracts was discussed and suggestions
for improvements made. RESULTS: A total of 237 ab-
stracts were identified, relating to the 20 topics specified
by the decision-makers. The number of relevant abstracts
per topic ranged from 0 to 32. Although a minority of
abstracts provided information of direct relevance to the
decision-makers’ original questions, the main uses were
more general, in identifying issues for further study and
providing information relevant to other questions. The
main suggestions for improvement in the published liter-
ature and the structured abstracts were to (i) increase the
generalizability of studies (ii) to address broader topics
and (iii) to develop a quality scoring system for economic
evaluations. CONCLUSIONS: The current published lit-
erature in economic evaluation is of use to decision-mak-
ers, but more attention needs to be given to understanding
decision-makers’ needs and to the quality and generaliz-
ability of studies.
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OBJECTIVES: to prepare a map of avoidable deaths in
Italy and to estimate the years of life lost (YLLs) for a
number of pathologies. METHODS: mortality was cal-
culated from data provided by the national statistic office
(ISTAT) for the year 1994. Causes of death were grouped
into 37 principal categories. All mortality rates are ex-
pressed as deaths/100,000 inhabitants, and were stan-
dardized by age and sex using the “direct” method. The
standardized mortality rate (SMR) was also calculated,
along with the estimate of the number of YLLs for each
cause of avoidable death, using ISTAT life expectancy ta-
bles. The various causes of death were then grouped into
3 different categories (deaths avoidable exclusively with
primary prevention intervention, avoidable with timely
diagnosis and appropriate therapy, avoidable with a mix
of prevention and therapy). RESULTS: data were used to
draw maps describing unhomogeneous avoidable death
rates and number of YLLs in different pathologies. For
instance, the mortality rate due to hypertension and cere-
brovascular accidents showed a higher value (about two-
fold) in Southern Italy than in Northern Italy; again, the
mortality rate of myocardial infarction showed a higher
value (about 1.5 times) in the Northern-East regions than
in Southern regions. Furthermore, it appears that in
Northern part of Italy avoidable deaths, in terms of YLLs,
are especially due to the lack of primary prevention inter-
ventions (i.e. mainly due to life style and environmental
factors), while in Southern Italy avoidable deaths due to
lack of timely diagnosis and appropriate treatment are
higher than in Northern Italy. CONCLUSION: our data
reflect different levels of health care existing among the
different Italian regions. This could represent the starting
point for improving the quality and the equity of the Na-
tional Health System.
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OBJECTIVE: Comparison of different drug regulation
systems for drugs administered in hospitals and paid by
community held budget: 1) authorization of drug prior
initiation of treatment b) setting clear guidelines for au-
thorization and reimbursement after treatment has been
started. METHOD: Drug consumption of individual drugs
that are controlled was compared before and after reim-
bursement using the DPC model. The DPC is defined as
cost of individual drug (or pharmacological group) for
one year divided by the total drug budget of the HMO.
The DPC was calculated for both regulatory systems for
the reimbursed drugs in 1998 and 1999. RESULTS: Ev-
ery year the National Health Insurance Law is updated
by adding new drugs and guidelines for reimbursement.
Each drug budgeted by the estimated number of patients
to be treated for specific indication. According to the
law, HMO’s may set limitations to control drug con-
sumption such as pre-authorization for specific indica-
tions. Sixteen drugs were budgeted at December 1997.
DPC of these drugs between 1998 to 1997 and between
1999 to 1998 was 1.37 and 1.33 respectively. The results
showed that the update process increased consumption
and reached to the plateau stage early then expected.
However, different behavior was observed with thirty-
eight drugs budgeted at March 1999. DPC of these drugs
between 1998 to 1997 and between 1999 to 1998 was
found to 1.39 and 1.63 respectively. For 2000 the fore-
casted DPC is 1.89. In the two mentioned updating, drug
regulation was always done before beginning the treat-
ment. In 2000, Trastuzumab was budgeted setting clear
guidelines and the control of the HMO’s after treatment
initiation. Trastuzumab consumption from the beginning
of the year shows that although no pre-authorization is
done, both number of patients and allocated resources
